DUSP22 and hepatocellular carcinoma: On the contrary, hepatic-specific DUSP22 overexpression considerably restrained NASH-associated HCC tumorigenesis in DEN/HFHC-treated mice with ameliorated NASH phenotypes (Fig. 8h–n).